
Embark Beyond's priority list has technological and interpersonal pieces
"We've really been focused on two main courses in our prediction of how to stay relevant in the next chapter," Ezon said, pointing to technology and "clienteling" -- the retail strategy of cultivating personal relationships with clients.
On the technology front, Danziger stressed that Embark sees it as additive for advisors.
"Agencies that don't embrace technology -- I think they're going to struggle in the next couple of years," she said. "But the ones who embrace it and figure out how to utilize it in the right way are really in for a treat."
In September, the agency will launch an AI-powered platform, Embark Blackbook, that takes its intranet "to another level," Ezon said. The platform, being built in-house, will be able to match client profiles with product profiles that Embark is currently building. It will also include a clienteling dashboard.
Ezon defines clienteling as "the luxury retail term for proactive, relationship-based marketing," and right now at Embark, "everything we're trying to do is build a clienteling mindset."
He wants advisors to be more proactive with customer relationships, something with which Blackbook will assist. It might suggest an article to send to a client because they love fishing, for example.
"It's not only about selling your product, it's about connecting with people," he said.
To that end, the agency has been bolstering its partnerships with luxury brands and creating experiences exclusive to Embark clients. For instance, they can go to Italy and meet with members of the Missoni family, who run the eponymous fashion house.
Embark is also working automotive brands, food and wine, among others. The agency is considering experiences with dogs as well as instituting a mahjong program surrounding the game that is enjoying a surge in popularity.
Advisors can also take advantage of new revenue sources negotiated by Embark for nontravel sales, like jewelry. Ezon said Embark is delivering high-end clients to activities like shopping experiences, so its advisors should make money on the transactions, too (commissions weren't a hard sell for the brands Embark has partnered with, he said, as "luxury brands have seen hospitality, more and more, as a perfect collaboration").
"We're trying to give our advisors more tools to talk to their customers in a deeper way, to things that they're passionate about," Ezon said. "So we have the technology, and we're creating the product to work around, to put marketing campaigns around, so that we can get a deeper trust and relationship with our clients that AI won't replace."
While Blackbook is in development now, Ezon said it likely always will be. He said it was designed to keep changing.
Hola, Mexico
Outside of technology and clienteling, Danziger said Embark is focused on developing new travel advisors and growing the agency. She is particularly excited about the diversity in new advisors.
"They're all bringing something so different to the table, and it's refreshing and it's exciting," she said. "The more we grow outside of a bubble, and the more different people, different cultures, we invite into our environment, the more exciting it is."
The agency also wants to expand its reach outside of the United States, and be less known as a U.S. or New York agency.
"I think that's where things are going within our industry," Danziger said. "It's more global and everything is more connected."
According to Ezon, Embark's first expansion will be into Mexico.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) jumped 3%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) jumped 3.5%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Globus Medical (NYSE:GMED) jumped 3%. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) jumped 3.4%. Is now the time to buy Neogen? Access our full analysis report here, it's free. Dental Equipment & Technology company Dentsply Sirona (NASDAQ:XRAY) jumped 3.1%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it's free. Zooming In On UFP Technologies (UFPT) UFP Technologies's shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 11.9% on the news that the company posted record second-quarter results and beat analyst profit expectations. The medical products company reported a 37.2% surge in sales to $151.2 million compared to the same period last year. Its adjusted earnings per share reached $2.50, which surpassed Wall Street's consensus estimate of $2.25. This strong performance was primarily driven by a 46% jump in its MedTech business, fueled by demand in areas like robotic-assisted surgery. However, the results included a 20% decline in its Advanced Components division, and the company noted increased labor costs pressured margins. UFP Technologies is down 10.2% since the beginning of the year, and at $221.03 per share, it is trading 38.3% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,057. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
21 minutes ago
- Yahoo
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Therapeutics company Moderna (NASDAQ:MRNA) jumped 3.1%. Is now the time to buy Moderna? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) jumped 4.1%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Dental Equipment & Technology company Envista (NYSE:NVST) jumped 3.1%. Is now the time to buy Envista? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 3.5%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Health Insurance Providers company UnitedHealth (NYSE:UNH) jumped 3%. Is now the time to buy UnitedHealth? Access our full analysis report here, it's free. Zooming In On Teleflex (TFX) Teleflex's shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock dropped 22.9% on the news that the company reported disappointing fourth-quarter results, with revenue missing expectations by a significant margin. On a constant currency basis, revenue increased 3.2%, but this still fell short of Wall Street's estimates. Weak demand in Interventional Urology wiped out gains in the Interventional and Surgical units. Looking ahead, the company's 2025 revenue guidance implies little to no growth, with management projecting revenue to be flat to slightly up. Overall, this was a weaker quarter, weighed down by sluggish growth, margin pressures, and a subdued outlook. Teleflex is down 32.8% since the beginning of the year, and at $120.33 per share, it is trading 51.3% below its 52-week high of $247.32 from September 2024. Investors who bought $1,000 worth of Teleflex's shares 5 years ago would now be looking at an investment worth $320.02. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
21 minutes ago
- Yahoo
Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Expedia Group's Fair Values from the Community and select yours Expedia Group (NASDAQ:EXPE) Second Quarter 2025 Results Key Financial Results Revenue: US$3.79b (up 6.4% from 2Q 2024). Net income: US$330.0m (down 14% from 2Q 2024). Profit margin: 8.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$2.61 (down from US$2.93 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Expedia Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Hospitality industry in the US. Performance of the American Hospitality industry. The company's shares are up 4.1% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Expedia Group's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data